LYEL insider trading
HealthcareLyell Immunopharma, Inc.: insider trade history from SEC Form 4 filings.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Company website: www.lyell.com
LYEL insider activity at a glance
FilingIQ tracks 85 insider transactions for LYEL in filings since Jun 23, 2021. The most recent transaction is dated Sep 10, 2026.
Across the full history, 8 open-market purchases
and 42 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LYEL insider trades is 57.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest LYEL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding LYEL
Frequently asked
- How many insider trades does FilingIQ track for LYEL?
- FilingIQ tracks 85 Form 4 insider transactions for LYEL (Lyell Immunopharma, Inc.), covering filings from Jun 23, 2021 onwards. 12 of those are dated within the last 90 days.
- Are LYEL insiders net buyers or net sellers?
- Across the full Form 4 history for LYEL, 8 transactions (9%) were open-market purchases and 42 (49%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LYEL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is LYEL in?
- Lyell Immunopharma, Inc. (LYEL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $522.81M.
Methodology & sources
Every LYEL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.